Skip to content

Tumor–Immune Dynamics in Peripheral Blood: Sustained Presence of Stemness-Associated Circulating Tumor Cells During Chemotherapy in Gastric Cancer

Sep 2026 · Natural Resources for Human Health · Vol 6, pp. 1082-1092 · 0 citations · 31 references

TL;DR

The RT-qPCR analysis of EpCAM, CD44, CD133, and CK19 indicates fluctuating circulating tumour cell (CTC) variations throughout treatment in gastric cancer, indicating the presence of persistent CTCs.

Abstract

Background: Circulatin Tumor Cells (CTCs) are promising indicators for gastric cancer tumour dynamics and therapy response. Epithelial and stemness-related gene expression can be detected with great sensitivity using RT-qPCR. This study measured EpCAM (CD326), CD44, CD133, and CK19 in gastric cancer patients' peripheral blood before and throughout chemotherapy and compared them to healthy controls. Methods: This prospective study had two primary groups: healthy controls (n = 20) and patients with stomach cancer (n = 75). Patient samples were obtained at three intervals: T0 (before to the initial chemotherapy cycle) n=25, T1 (prior to the third cycle) n=25, and T2 (subsequent to the last cycle) n=25. Peripheral blood mononuclear cells were extracted using Ficoll-Paque density gradient centrifugation, subsequently followed by RNA extraction and cDNA synthesis. RT-qPCR quantified the expression of EpCAM, CD44, CD133, and CK19, normalised to GAPDH. The cut-off values for CTC positive were established as the mean plus two standard deviations of healthy controls. Results: In healthy controls, the mean ± SD expression levels were as follows: EpCAM: 0.15 ± 0.05, CD44: 0.25 ± 0.08, CD133: 0.10 ± 0.04, and CK19: 0.12 ± 0.06. The positivity cut-offs were determined to be 0.25, 0.41, 0.18, and 0.24, respectively. At baseline (T0), patient values were significantly elevated: EpCAM (8.00 ± 1.10), CD44 (6.00 ± 1.48), CD133 (10.00 ± 0.96), and CK19 (12.00 ± 0.153). Notable reductions were recorded at T1 and T2, with the most pronounced decreases for EpCAM and CK19. All markers consistently exceeded their respective cut-off thresholds at T2, indicating the presence of persistent CTCs. The decline of stemness-associated markers CD44 and CD133 was slower, indicating the presence of chemoresistant subpopulations. Conclusion: The RT-qPCR analysis of EpCAM, CD44, CD133, and CK19 indicates fluctuating circulating tumour cell (CTC) variations throughout treatment in gastric cancer. EpCAM and CK19 diminish swiftly with therapy, signifying a reduction in bulk epithelial circulating tumour cells (CTCs), whereas CD44 and CD133 remain, possibly indicating the presence of residual stem-like CTCs and an increased risk of recurrence. Ongoing molecular positive despite clinical intervention underscores the necessity for integrated therapeutic approaches aimed at chemoresistant circulating tumour cells (CTCs).

View source

Similar papers

Open access Sep 2026

The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients

These findings provide a comprehensive characterization of CTCs and CTACs in PC using a multiplex biomarker panel associated with calcium signaling and immune checkpoint pathways, highlighting the pronounced heterogeneity and potential clinical relevance of these circulating cell populations.

Chrysoula Tagari, Karolina Mangani, Michael Gogolides et al. · 0 citations
Open access Sep 2026

The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.

Investigation of the critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin in promoting SCLC metastasis concluded that Vim+ CTECs serve as a key driver of tumor metastasis in SCLC.

Ying Wang, Fei Qi, Ming-Hang Zhang et al. · 0 citations
Open access Sep 2026

Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance

Abstract Background Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1+CD8+ T cells, cytotoxic CD8+ T cells, and lymphoid aggregates have been associated with CPB responsiven...

C. Minnar, Masaya Miyamoto, Asma S. Khelifa et al. · 0 citations
Open access Sep 2026

Single-cell transcriptomic characterization of the immunosuppressive tumor immune microenvironment in hepatocellular carcinoma: implications for SBRT-based radio-immunotherapy

The HCC TIME is profoundly immunosuppressive, driven by myeloid dominance and multi-checkpoint T cell exhaustion, providing direct mechanistic rationale for combining macrophage reprogramming, dual checkpoint blockade, and anti-angiogenic strategies with SBRT.

Xiao-Fei Zhang, Xiao-Han Ma, Sheng Chen et al. · 0 citations
Sep 2026

Abstract B115: Divergent T cell exhaustion dynamics in periphery versus tumor during neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a five-year survival rate of 13%. Neoadjuvant therapy (NAT) is thought to reshape anti-tumor immunity, but its effects on circulating T cell composition/exhaustion and how this relates to intratum...

Umayal Sivagnanalingam, Renee R. Anderko, C. Arora et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.